Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- SOFI -11.8%
Select Index ETFs showing weakness:
- QQQ -3.8%, SPY -2.2%, IWM -1.2%, DIA -0.9%
Select tech names showing early weakness:
- NVDA -12.1%, ARM -10.5%, MSFT -6%, AI -5.7%, XLK -4.8%, AMD -4.4%, META -3.4%
Other news:
- VERU -38.8% (Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY (Semaglutide) for Weight Reduction)
- MVST -15.1% (files for $250 mln mixed securities shelf offering)
- KULR -6.5% (increased the maximum offering amount of the shares issuable under the At The Market Offering Agreement to $100,000,000 from $50,000,000; filed a prospectus supplement under the Sales Agreement for an aggregate of $50 mln)
- MSTR -5.6% (sold an aggregate of 2,765,157 Shares under the Sales Agreement during the period between January 21, 2025 and January 26, 2025)
- ECOR -3.5% (files $100 mln mixed shelf securities offering)
- NTRA -3.3% (Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer)
- KOPN -3% (enters into $50 mln At-The-Market Equity Offering Sales Agreement)
- PRTC -2.5% (Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine)
- SLDB -2.5% (provided DOE update)
- SRPT -1.7% (Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS)
- X -1.7% (reiterates commitment to maximizing value for stockholders; issues statement in response to Ancora)
- HTH -1.7% (announces agreement to sell its interest in Moser Energy Systems)
- MIDD -1% (confirms ongoing strategic review of business portfolio as part of Board of Directors' efforts to maximize shareholder value)